Optimizing Lipid Lowering Strategies: Navigating the Evolving Landscape

Optimizing Lipid Lowering Strategies: Navigating the Evolving Landscape

This multi-format educational curriculum is designed for self-paced online education with an overall goal of ensuring clinicians can develop a treatment plan for high risk ASCVD patients that would benefit from aggressive lipid management.

Learners can use their ACC.org login to open these non-certified activities. New visitors will be directed to create a free account as they open their first activity.

	Practical Tips for Prior Authorizations: A Discussion with the Experts (16 min) Hear how the experts successfully navigate common barriers to prior authorizations for PCSK9 inhibitors. Learn how to leverage EHRs and online resources to support prior authorization approvals and effective appeals. Watch faculty share best practices for streamlining the process for both colleagues and patients.
	Follow the Science: Refining Risk Assessment in ASCVD (11 min) Clinical experts break down how and why the guidelines established the characteristics of very-high risk patients and the concept of “high risk features” in ASCVD per recent clinical trials, and how to personalize lipid-lowering therapy for your patients based on risk.
	Intensification of LDL-C Lowering Therapies: Identifying the Very High-Risk Patient (an Interactive Learning Tool) (20 min) This interactive learning activity walks users through risk assessment and associated treatment intensification to develop a guideline-driven treatment plan that optimizes therapy for ASCVD patients. Through the use of case studies, learners will challenge their knowledge and reinforce key concepts in secondary prevention.
	Transforming LDL-C Risk: Role of Nonstatin Therapies (12 min) Hear from the experts as they discuss the role of nonstatin therapies according to the 2018 clinical practice guidelines on Cholesterol. Gain clarity on the concept of lipid thresholds, and how they differ from lipid targets and goals, and review how to manage nonstatin therapies for patients based on their ASCVD risk.
	PCSK9 Inhibitors: The What, How, and Wow! (31 min) Gain insights into the fascinating science behind PCSK9 inhibitors through this narrated presentation. Dr. Kim Birtcher’s deep-dive into the evidence from the FOURIER and ODYSSEY clinical trials and a visualization of the mechanism of action will help you more precisely prescribe and dose PCKS9 inhibitors for your patients.

We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection.

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA (Chair)
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina

Alison Bailey, MD, FACC
Director, Preventive Cardiology & Cardiac Rehabilitation
UT COM Chattanooga
Erlanger Heart & Lunch Institute

Nicole Lohr, MD, PhD, FACC
Associate Professor of Medicine
Medical College of Wisconsin

Kim K. Birtcher, PharmD, MS, AACC, FNLA
Clinical Professor
University of Houston College of Pharmacy

Roger S. Blumenthal, MD, FACC
Director, Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins Hospital

Carl E. Orringer, MD, FACC
Associate Professor of Medicine
Director, Preventive Cardiovascular Medicine
Cardiovascular Division
University of Miami Miller School of Medicine

Educational grant support provided by REGENERON